QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
An important new study found that for men having prostate biopsies, MRI-ultrasound fusion targeted biopsies could improve detection of clinically significant prostate cancer. An MR-fusion prostate biopsy combines magnetic resonance imaging (MRI) and ultrasound imaging to target more suspicious lesions…
The proposal defined non- recommended PSA testing according to the guidelines released by the United States Preventive Services Task Force (USPSTF) in 2012. These guidelines recommend against the use of routine PSA testing in otherwise healthy men of all ages,…
The researchers’ analysis included 19 studies that pooled data on up to 118,830 patients. For overall cause of death, the adjusted hazard ratio for patients treated with radiation versus surgery was 1.63. For prostate cancer-specific death, the adjusted hazard ratio…
The TERRAIN trial included 375 patients with asymptomatic or minimally symptomatic metastatic CRPC who were randomly assigned to take enzalutamide or bicalutamide. Men in the enzalutamide group had significantly improved progression-free survival (median 15.7 months vs. 5.8 months). Xtandi (enzalutamide)…
The researchers examined the records of 37,687 men in the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Of the 3,656 men who chose to leave their cancers untreated, only 4.5% were being monitored appropriately. The study defined recommended follow-up care…
However, a new study from the University of Texas Medical Branch found no link between exposure to testosterone during a 5-year period and an increased risk of aggressive prostate cancer. The authors believe that this is the first population- based…
Researchers at Johns Hopkins assessed PHI values in 80 African- American patients with PSA values of 2-10 ng/ml prior to their radical prostatectomies. Twenty percent of the men had pathological stage 3 (pT3) prostate cancers. Although age, PSA and percentage-free…
Jim Sansone knows firsthand that prostate cancer affects the whole family. Nearly 25 years ago, he supported his father, URF board president Anthony Sansone, Sr., through prostate cancer treatment. His father remains healthy today, and now Jim serves on the…
The URF is pleased to welcome Col. Allen B. West to its Board of Trustees. Col. West works in public policy and is a retired military serviceman, published author and former U.S. congressman. He has pledged to be a voice…
On March 21, Dr. William Catalona received a 2016 Castle Connolly National Physician of the Year Award for Clinical Excellence at the historic Pierre Hotel in New York City. Each year, Castle Connolly Medical Ltd. recognizes both physicians and leaders…
"*" indicates required fields
